The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence through Experience1-12
IRIS is an observational, retrospective medical chart review study of 1723 adult female patients (data as of May 2020) treated with IBRANCE®▼ (palbociclib) combination treatments in line with locally licensed indications across 21 planned countries in North America, South America and Europe.1,11-13
The IRIS study aims to evaluate the demographics, clinical characteristics, treatment patterns and outcomes of IBRANCE® combinations in diverse, real-world HR+ HER2- aBC/mBC patient populations.1,11-13
Index date is 60 days after the physical first prescribed IBRANCE® with partner therapy following approval.
Observational retrospective analyses are designed to evaluate associations among variables and cannot establish causality. Observational retrospective analyses are not intended for direct comparison with clinical trials.9,10
Data from the IRIS UK cohort demonstrate that palbociclib + AI or fulvestrant in the treatment of peri- and postmenopausal women with aBC/mBC is effective and well tolerated in real-world clinical practice1
IRIS UK cohort outcomes are consistent with results from the PALOMA clinical trials1–7
† 255 patients in the IRIS UK cohort: 221 patients received IBRANCE® plus AI, survival rate 92.2%; 34 patients received IBRANCE® plus fulvestrant: survival rate 85.2%, the calculated weighted average is 91.3%
In the UK, 34 physicians reviewed and extracted data from medical records for 255 patients treated with IBRANCE® plus AI (n=221) or IBRANCE® plus fulvestrant (n=34).1
* EMA approval on 10 November 2016
† Index dates vary by physician depending on the date first prescribed
‡ EMA approval on 10 November 2016 but NICE approval was not received until October 2019; therefore, availability to some physicians may have been limited before this time.
Patient baseline characteristics in the IRIS (UK) cohort were representative of a real-world patient population and similar to patients in the PALOMA clinical trials.1-3
Median age was 65 overall, and approximately one quarter of UK patients in the IRIS Study were over 70 years of age and 98% were in menopause.
* Additional sites of metastasis included skin/soft tissue, ovary and other (7.9%, 0.4% and 5.0% of the overall population, respectively).
Overall, 50.2% of patients with metastases had visceral disease (n=120), and the most frequent site of metastasis was bone (70.7%)1
In the real-world setting of the IRIS (UK) observational, retrospective chart review, IBRANCE® in combination with AI/Fulvestrant demonstrated favourable efficacy in progression-free rates.1
The 12-month progression-free rates observed in the IRIS UK cohort were1 :
- 85.3% in patients receiving IBRANCE® + AI
- 74.5% in patients receiving IBRANCE® + fulvestrant
* Progression-free rate estimated via Kaplan–Meier analysis.
PFR in patients enrolled in the IRIS (UK) cohort was established by assessing time from initiation until the earliest of:1
- Clinician-documented progression while on treatment with IBRANCE®
- Start of a new therapy line after final IBRANCE® dose if the reason for discontinuation of IBRANCE® was disease progression
- Last available follow-up
In the real-world setting of the IRIS (UK) observational, retrospective chart review, IBRANCE® in combination with AI/Fulvestrant demonstrated favourable efficacy in survival rates.1
In the IRIS (UK) cohort, 9 out of 10 patients are alive at 2 years (weighted with median patient numbers*).1
* Survival rates estimated via Kaplan–Meier analysis.
Time from the date of initiation of palbociclib combination therapy to the date of death due to any cause or end of follow-up (if earlier).
Consistent with PALOMA clinical trials, palbociclib appears to be well tolerated in clinical practice.2-8
Dose reductions were less common in the IRIS (UK) cohort than in the PALOMA clinical trials.4–6
- Treatment was discontinued in 21.7% of patients receiving palbociclib + AI and 17.6% of patients treated with palbociclib + fulvestrant1
- The most common reason for discontinuation was disease progression following initial response (82.4%)1
Permanent discontinuation of palbociclib due to AEs was 2% in the IRIS UK cohort1
Dose reductions in patients treated with palbociclib in the IRIS UK cohort were infrequent.1
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Real-world patient data for IBRANCE® in advanced Breast Cancer
IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020